You're describing a compound with the chemical name **2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1H-benzimidazole**. This compound is likely an **imidazo[1,2-a]pyridine derivative**, a class of molecules with diverse biological activity.
Let's break down its structure and potential importance:
* **Imidazo[1,2-a]pyridine:** This is a bicyclic heterocycle, meaning it contains two fused rings with atoms other than carbon (nitrogen in this case).
* **2-(2-imidazo[1,2-a]pyridinylmethylthio):** This part of the name describes a substituent attached to the benzimidazole ring. It indicates a 2-imidazo[1,2-a]pyridinylmethyl group connected through a sulfur atom (thio).
* **6-nitro-1H-benzimidazole:** This describes the core structure of the compound. It's a benzimidazole ring with a nitro group (NO2) at position 6.
**Importance for Research:**
Imidazo[1,2-a]pyridine derivatives have been extensively researched for their potential applications in medicine, particularly as:
* **Anti-cancer agents:** Some derivatives have shown promising activity against various types of cancer, including leukemia, lung cancer, and breast cancer.
* **Anti-inflammatory agents:** This class of compounds can inhibit inflammatory pathways, making them potentially useful for treating inflammatory diseases like rheumatoid arthritis.
* **Antimicrobial agents:** Certain imidazo[1,2-a]pyridine derivatives exhibit activity against bacteria, fungi, and viruses.
* **Neuroprotective agents:** Some derivatives have shown promise in protecting nerve cells from damage, potentially offering therapeutic benefits for neurological disorders.
**Important Considerations:**
It's crucial to note that the specific compound you mentioned (2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1H-benzimidazole) might not have been specifically studied for its biological activity.
To determine its potential importance, you would need to:
1. **Identify the source:** Where did you encounter this compound? Is it mentioned in a research article or patent?
2. **Check for published data:** Search scientific databases (PubMed, Google Scholar, etc.) to see if there's any research on its biological activity.
3. **Analyze its structure:** Examine its structural features and compare them to known imidazo[1,2-a]pyridine derivatives with known biological effects. This can provide clues about its potential activity.
In summary, 2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1H-benzimidazole is a potential candidate for further research due to the known diverse biological activities of imidazo[1,2-a]pyridine derivatives. However, its exact potential and importance remain to be investigated.
ID Source | ID |
---|---|
PubMed CID | 916344 |
CHEMBL ID | 1451126 |
CHEBI ID | 105775 |
Synonym |
---|
EU-0073050 |
smr000212094 |
MLS000588280 |
2-(imidazo[1,2-a]pyridin-2-ylmethylsulfanyl)-5-nitro-1h-benzoimidazole |
OPREA1_342671 |
STK361603 |
2-[(imidazo[1,2-a]pyridin-2-ylmethyl)sulfanyl]-5-nitro-1h-benzimidazole |
CHEBI:105775 |
AKOS002285125 |
2-(imidazo[1,2-a]pyridin-2-ylmethylsulfanyl)-6-nitro-1h-benzimidazole |
HMS2542I20 |
F1001-0013 |
328016-66-6 |
2-((imidazo[1,2-a]pyridin-2-ylmethyl)thio)-5-nitro-1h-benzo[d]imidazole |
CHEMBL1451126 |
Q27183552 |
2-(2-imidazo[1,2-a]pyridinylmethylthio)-6-nitro-1h-benzimidazole |
sr-01000446815 |
SR-01000446815-1 |
2-[({imidazo[1,2-a]pyridin-2-yl}methyl)sulfanyl]-5-nitro-1h-1,3-benzodiazole |
Class | Description |
---|---|
imidazopyridine | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glp-1 receptor, partial | Homo sapiens (human) | Potency | 28.1838 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.3564 | 0.0041 | 10.8903 | 31.5287 | AID504466 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 3.5481 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 50.1187 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 10.0000 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 19.9526 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |